<DOC>
	<DOCNO>NCT01720316</DOCNO>
	<brief_summary>The purpose study assess efficacy oral glycine augmentation strategy two psychotic patient triplication ( 4 copy ) gene glycine decarboxylase ( GLDC ) . Subjects first undergo double-blind placebo-controlled clinical trial one 6-week arm involve glycine ( maximum daily dose 0.8 g/kg , administer TID dose schedule ) one 6-week arm involve placebo . A 2-week period treatment occur treatment arm . A 6-week period open-label glycine ( maximum daily dose 0.8 g/kg , administer TID dose schedule ) follow double-blind placebo-controlled clinical trial . Prior double-blind placebo-controlled clinical trial end open-label glycine trial , follow procedure carry : structural MRI ( 3T ) , Proton 1H MRS ( 4T ) , fMRI ( 3T ) , steady-state visual evoke potential , EEG . Positive , negative , affective symptom neurocognitive function well plasma level large neutral large small neutral excitatory amino acid psychotropic drug level assess periodically . In addition , 1H MRS ( 4T ) 2 hour single oral dose glycine-containing drink assess baseline . Pharmaceutical grade glycine powder ( Ajinomoto ) placebo dissolve 20 % solution prepare McLean Hospital Pharmacy . Because result double-blind placebo-controlled open-label glycine treatment arm show substantial clinical benefit participant , study extend include six month chronic open-label glycine order determine 1 ) whether clinical benefit achieve within 6 week previously recur , 2 ) clinical benefit last , 3 ) additional clinical benefit occur long exposure . The glycine extension provide Letco Medical . The investigator hypothesize mutation carrier reduce endogenous brain glycine GABA level increase brain glutamate glutamine level . Glycine administration increase brain glycine two carrier , less extent non-carrier family member control . The investigator hypothesize reduce activation magnocellular pathway abnormal ERPs modulate NMDA mutation carrier compare non-carrier family member control . The investigator hypothesize glycine , placebo , improve positive , negative affective symptom well neurocognitive function . The investigator also hypothesize open-label glycine improve clinical cognitive functioning , partially normalize decreased baseline glycine GABA increase glutamate glutamine , partially normalize magnocellular pathway activation abnormal evoked potential .</brief_summary>
	<brief_title>Neurobiology Mutation Glycine Metabolism Psychotic Disorders</brief_title>
	<detailed_description>Multiple rare structural variant relatively recent evolutionary origin recognize important risk factor schizophrenia ( SZ ) neurodevelopmental disorder ( e.g. , autism spectrum disorder , mental retardation , epilepsy ) odds ratios high 7-30 ( Sebat et al . 2009 ; Malhotra et al . 2011 ; Heinzen et al . 2010 ; Weiss et al . 2008 ; McCarthy et al . 2009 ) . We find de novo structural rearrangement chromosome 9p24.1 two psychotic patient . One gene region gene encode glycine decarboxylase ( GLDC ) , affect brain glycine metabolism . GLDC encode glycine decarboxylase glycine cleavage system P-protein , involve degradation glycine glia cell . Carriers GLDC triplication would expect low level brain Gly , result NMDA receptor-mediated hypofunction , strongly implicate pathophysiology schizophrenia ( Olney &amp; Farber , 1995 ; Coyle , 2006 ; Javitt , 2007 ) . There extensive literature effect NMDA enhance agent positive , negative , depressive symptom neurocognitive function ( see Tsai &amp; Lin , 2010 ; Lin et al . 2011 review ) . Although many study report positive result least one symptom domain ( Heresco-Levy et al . 1996 , 1999 , 2004 ; Tsai et al . 1998 , 1999 , 2004 , 2006 ; Javitt et al . 2001 ; Goff et al . 1996 ; Lane et al . 2008 ) , result study negative ambiguous ( Goff et al . 1999 ; Evins et al . 2000 ; Duncan et al . 2004 ; van Berckel et al . 1999 ) . Factors likely contribute variability include : mechanism action agent , compliance , concurrent treatment first- vs second generation antipsychotic drug , baseline glycine blood level , presence/absence kynurenine pathway metabolic abnormality ( Wonodi et al . 2010 ; Erhardt et al . 2007 ) individual difference brain glycine uptake metabolism ( Kaufman et al . 2009 ; Buchanan et al . 2007 ) . Genetic variant impact synthesis breakdown glycine , glutamate , modulators NMDA receptor function also likely significant effect . Although glycine augmentation show variable efficacy patient unselected mutation would expect low brain glycine level , GLDC triplication two carrier study would expect result unusually low brain glycine level , support therapeutic potential augmentation strategy . Thus , important evaluate therapeutic efficacy glycine augmentation individual high prior probability therapeutic benefit characterize neurobiology mutation term brain metabolite , brain function , pharmacokinetics glycine metabolism use well-established method ( Kaufman et al . 2009 ; Prescot et al . 2006 ; Martinez et al . 2008 ; Butler et al . 2001 ; Jensen et al . 2009 ; Ongur et al . 2008 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Triplication glycine decarboxylase gene Normal glycine decarboxylase copy number</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glycine</keyword>
	<keyword>Glycine decarboxylase</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Mutation</keyword>
</DOC>